source
- China’s five-year plan positions it to become a global leader in innovative biopharma by 2030China’s latest five‑year plan sets an ambitious target to turn the country into a major source of innovative medicines for the world market. Experts cited by BioSpace say the goal is within reach,…
- Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator leadAbbott has received both FDA and CE Mark approval for its UltiSynq defibrillation lead tech, which is designed to deliver both conduction system pacing and defibrillation therapy.